Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy

Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D). Case Presentation: The patient was a 68-year-old male T2D fatty liver several years. In November 2022, his HbA1c had increased to 8.2%, he started on Twymeeg, followed by EquMet. Results: Over the course of four months, patient’s value successfully decreased from 8.2% 6.7%, did not experience any gastrointestinal adverse effects (GIAEs). Discussion Conclusion: combined treatment EquMet Twymeeg demonstrated clinical efficacy without effects. Trials IMeglimin Efficacy Safety (TIMES) provided various evidence imeglimin’s effectiveness.